Business context and reporting period
Issuer mismatch: The supplied filing is Ruthigen, Inc.’s Form 10-Q, not a Pulmatrix filing. It covers the three months ended June 30, 2014, with a comparable 2013 period; the filing identifies Ruthigen as a development-stage biopharmaceutical company. The statements are unaudited.
Ruthigen is developing RUT58-60, a hypochlorous-acid-based anti-infective intended initially to prevent infections associated with abdominal surgery. It had no approved products and reported no revenue.
Financial results and liquidity
| Metric | Three months ended June 30, 2014 | Three months ended June 30, 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $676,000 | $175,000 |
| Selling, general and administrative | $1,043,000 | $302,000 |
| Total operating expenses | $1,719,000 | $477,000 |
| Operating loss | $(1,719,000) | $(477,000) |
| Net loss | $(1,715,000) | $(477,000) |
| Basic and diluted loss per share | $(0.36) | $(0.24) |
| Net cash used in operations | $(1,638,000) | $(329,000) |
At June 30, 2014, cash was $14.267 million, working capital $14.094 million, total assets $14.647 million, and current liabilities $550,000. Cash declined $1.304 million from March 31. The filing reports no debt; current liabilities included $7,000 payable to the former parent. No revenue means gross margin is not applicable.
Changes versus the prior comparable period
Operating expenses increased $1.242 million, or about 260%; R&D rose 286% and SG&A rose 245%. Management attributed the increases to RUT58-60 development and clinical-trial preparation, expanded clinical and regulatory activity, public-company legal, accounting and insurance costs, and stock compensation. Net loss increased from $477,000 to $1.715 million. Operating cash use rose from $329,000 to $1.638 million.
Financing cash flow included $865,000 net IPO proceeds and a $530,000 repayment of advances from the former parent. The company issued 154,290 additional shares through the IPO over-allotment, ending the quarter with 4,804,290 shares outstanding.
Outlook, risks, and unusual items
- Management expected existing cash to fund operations into the quarter ending December 31, 2015, but said further financing would be needed to execute its development and regulatory strategy. No additional financing commitment had been secured; inability to raise capital could force reduced or delayed programs.
- Management estimated total operating expenses of approximately $50 million to bring RUT58-60 through its goal of FDA approval. This is an estimate, not a guarantee.
- The IND became effective in June 2014. A 21-day skin-irritation study began in July and was completed in August with 36 participants. Management planned a 20-patient Phase 1 safety run-in followed, subject to data review, by Phase 2 enrollment. It anticipated an NDA submission in late 2017 if development and pivotal trials succeeded.
- Drug approval is uncertain and may take years; trial results, regulatory requirements, development costs, financing availability, competition, and potential partnerships could affect plans. No collaboration had been secured.
- The Oculus license could require up to $8 million in milestone payments upon specified conditions; none was accrued at June 30. Potential cash severance under key executive agreements was $1.144 million. The CFO agreement provides specified severance and equity-vesting terms in certain termination circumstances.
- Other notable items: stock-based compensation was $155,000; the company reported no material legal proceedings, no material changes to previously disclosed risk factors, and no material off-balance-sheet arrangements. Management stated disclosure controls were effective.
Most important facts for investors to verify
- Confirm issuer identity: this source is Ruthigen, Inc., not Pulmatrix, and confirm the intended reporting period.
- Check cash burn and financing needs against the stated runway through December 2015, including any later capital raises or spending changes.
- Verify subsequent clinical-trial progress, safety findings, DMC recommendations, FDA interactions, and whether projected trial and NDA timelines were achieved.
- Assess the assumptions behind the approximately $50 million development-cost estimate and the potential $8 million Oculus milestones.
- Review share dilution, including outstanding warrants, options, and restricted stock units; at June 30 the filing disclosed 3,145,650 warrants, 332,500 options, and 409,355 RSUs.